Aldosterone activates endothelial exocytosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 10, 2009, Pages 3782-3787

  Jeong, Youngtae ^a   Chaupin, Damian F ^a   Matsushita, Kenji ^a   Yamakuchi, Munekazu ^a   Cameron, Scott J ^a   Morrell, Craig N ^a   Lowenstein, Charles J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Mineralocorticoid; Nitric oxide; P selectin; Vascular

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; DACTINOMYCIN; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR BLOCKING AGENT; PADGEM PROTEIN; SMALL INTERFERING RNA; SPIRONOLACTONE; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ALDOSTERONE RELEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXOCYTOSIS; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKOCYTE ADHERENCE; LYMPHOCYTE TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RECEPTOR BINDING; VASCULITIS; WEIBEL PALADE BODY;

ALDOSTERONE; CALCIUM SIGNALING; CELL COMMUNICATION; ENDOTHELIAL CELLS; EXOCYTOSIS; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; LEUKOCYTES; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; WEIBEL-PALADE BODIES;

EID: 62649094917     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804037106     Document Type: Article

References (54)

1. Cohn JN, Colucci W (2006) Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 97:4F-12F.
2. Brown NJ (2008) Aldosterone and vascular inflammation. Hypertension 51:161-167.
3. Ferrario CM, Strawn WB (2006) Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98:121-128.
4. Fiebeler A, Muller DN, Shagdarsuren E, Luft FC (2007) Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr Opin Nephrol Hypertens 16:134-142.
5. Funder JW (2006) Minireview: Aldosterone and the cardiovascular system: Genomic and nongenomic effects. Endocrinology 147:5564-5567.
6. Funder JW (2007) The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 7:151-157.
7. Young MJ (2008) Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 17:174-180.
8. Weber KT, et al. (2003) Aldosteronism in heart failure: A proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets 4:505-516.
9. Funder JW (2004) Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 217:263-269.
10. Fiebeler A, Luft FC (2005) The mineralocorticoid receptor and oxidative stress. Heart Fail Rev 10:47-52.
11. Joffe HV, Adler GK (2005) Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 10:31-37.
12. Duprez DA (2006) Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. J Hypertens 24:983-991.
13. Savoia C, Schiffrin EL (2007) Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 112:375-384.
14. Young MJ, Lam EY, Rickard AJ (2007) Mineralocorticoid receptor activation and cardiac fibrosis. Clin Sci (Lond) 112:467-475.
15. Blasi ER, et al. (2003) Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791-1800.
16. Neves MF, et al. (2005) Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 83:999-1006.
17. Benetos A, Lacolley P, Safar ME (1997) Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 17:1152-1156.
18. Rocha R, et al. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H1802-H1810.
19. Lacolley P, et al. (2001) Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 37:662-667.
20. Oestreicher EM, et al. (2003) Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 108:2517-2523.
21. Kuster GM, et al. (2005) Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 111:420-427.
22. Irita J, et al. (2006) Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 19:293-297.
23. Clapp BR, et al. (2005) Inflammation and endothelial function: Direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 111:1530-1536.
24. Luther JM, et al. (2006) Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 48:1050-1057.
25. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ (2002) Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 87:448-452.
26. Jaffe IZ, Mendelsohn ME (2005) Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96:643-650.
27. Fejes-Toth G, Naray-Fejes-Toth A (2007) Early aldosterone-regulated genes in cardiomyocytes: Clues to cardiac remodeling? Endocrinology 148:1502-1510.
28. Calo LA, et al. (2004) Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab 89:1973-1976.
29. Hirono Y, et al. (2007) Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: The possible role of local renin-angiotensin system. Endocrinology 148:1688-1696.
30. Leopold JA, et al. (2007) Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13:189-197.
31. Caprio M, et al. (2008) Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102:1359-1367.
32. Grossmann C, Gekle M (2008) Nongenotropic aldosterone effects and the EGFR: Interaction and biological relevance. Steroids 73:973-978.
33. Brown NJ (2005) Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14:235-241.
34. Harvey BJ, et al. (2008) Rapid responses to aldosterone in the kidney and colon. J Steroid Biochem Mol Biol 108:310-317.
35. Wehling M (1997) Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 59:365-393.
36. Haseroth K, et al. (1999) Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. Biochem Biophys Res Commun 266:257-261.
37. Min LJ, et al. (2005) Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97:434-442.
38. Mihailidou AS, Mardini M, Funder JW (2004) Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 145:773-780.
39. Alzamora R, Brown LR, Harvey BJ (2007) Direct binding and activation of protein kinase C isoforms by aldosterone and 17beta-estradiol. Mol Endocrinol 21:2637-2650.
40. Alzamora R, Harvey BJ (2008) Direct binding and activation of protein kinase C isoforms by steroid hormones. Steroids 73:885-888.
41. Lowenstein CJ, Morrell CN, Yamakuchi M (2005) Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 15:302-308.
42. Rondaij MG, et al. (2006) Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 26:1002-1007.
43. Emeis JJ, et al. (1997) An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 139:245-256.
44. Sun Y, et al. (2002) Aldosterone-induced inflammation in the rat heart: Role of oxidative stress. Am J Pathol 161:1773-1781.
45. Christ M, Meyer C, Sippel K, Wehling M (1995) Rapid aldosterone signaling in vascular smooth muscle cells: Involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun 213:123-129.
46. Liu SL, et al. (2003) Aldosterone regulates vascular reactivity: Short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108:2400-2406.
47. Callera GE, et al. (2005) Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45:773-779.
48. Christ M, et al. (1995) Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension 25:117-123.
49. Knop M, Aareskjold E, Bode G, Gerke V (2004) Rab3D and annexin A2 play a role in regulated secretion of vWF, but not tPA, from endothelial cells. EMBO J 23:2982-2992.
50. Takebayashi K, Matsumoto S, Aso Y, Inukai T (2006) Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 91:2214-2217.
51. Brown NJ, et al. (1998) Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 32:965-971.
52. Godfrey V, et al. (2007) Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol 117:282-284.
53. Savoia C, Touyz RM, Amiri F, Schiffrin EL (2008) Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 51:432-439.
54. Matsushita K, et al. (2003) Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 115:139-150.